ObvioHealth and Oracle Life Sciences are set to broaden their collaboration, aiming to globalise digital clinical trials.
The partnership will facilitate gathering, integration, and assessment of diverse trial health data from around the world. The data are sourced from clinicians, participants, devices, and labs.
The latest deal expansion aligns with the launch of ObvioHealth’s new digital clinical trial platform and mobile application, ObvioGo 2.0.
This product features a code-free study design platform with advanced multi-lingual capabilities.
These enhancements will allow for the translation and confirmation of electronic Clinical Outcome Assessments (eCOA) and study app interfaces into any left-to-right language.
The eCOA data from the ObvioGo platform is transmitted on a real-time basis into Oracle’s Clinical One solution.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
This integration ensures that remote participant and site-based clinical evaluations are rapidly available for monitoring.
ObvioHealth CEO Ivan Jarry said: “The expansion of ObvioGo, in partnership with Oracle, is an important step towards truly globalising digital trials.
“Sponsors will benefit from the ability to capture data at home, in-clinic, or while participants are on the go, alongside Clinical One’s robust data management, at a global scale.”
This initiative follows a successful year of unveiling such trials in the Asia Pacific region.
In October 2022, the companies initially collaborated with a focus on the Asia Pacific market.
Since the announcement, the companies have successfully launched multiple trials.
A notable achievement is the completion of a Phase I study that assessed the safety and immunogenicity of a vaccine candidate for the Sudan Ebola virus.
During this trial, participants utilised the ObvioGo app to remotely report injection site reactions and health status changes.
The data collected from both at-home and site-based sources were subsequently consolidated into the Oracle Clinical One platform.
Oracle Life Sciences Alliances & Channels global vice-president Drew Zwiebel said: “Our newly expanded partnership with ObvioHealth will bring greater access, equity, and data availability to clinical trials globally.
“By combining our centralised capabilities with ObvioHealth’s next-gen digital platform, we’re helping to make clinical trials more patient-centric and efficient.”